Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01477424 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of Warfarin and PA21
A Phase 1 study of Drug Interaction Potentiation, sponsored by Vifor Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT01477424: Completed Phase 1 study of Drug Interaction Potentiation, sponsored by Vifor Pharma.
NCT01477424 is a Phase 1 study of Drug Interaction Potentiation that has completed, run by Vifor Pharma. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01477424, a Phase 1 study of Drug Interaction Potentiation, has completed, sponsored by Vifor Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if Warfarin is affected by PA21.
Primary Outcome
Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours
Conditions Studied
Interventions
- DRUG Warfarin
- DRUG PA21
Study Locations (1)
Kansas
- PRA International - Clinical Pharmacology Center - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
What the finished NCT01477424 record still lists
NCT01477424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Drug Interaction Potentiation appearing as the primary indexed condition, and to 2 interventions - of which Warfarin is the first listed.
NCT01477424 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01477424 about?
NCT01477424 is a clinical study titled "A Drug-Drug Interaction Study of Warfarin and PA21". The purpose of this study is to determine if Warfarin is affected by PA21.
What is the current status of trial NCT01477424?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2011-11. Estimated completion is 2012-02.
What conditions does trial NCT01477424 study?
This clinical trial studies the following conditions: Drug Interaction Potentiation.
What interventions are being tested in trial NCT01477424?
The interventions under investigation include: Warfarin (DRUG), PA21 (DRUG).
Who is sponsoring clinical trial NCT01477424?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01477424 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01477424's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia